Every material Form 8-K Co-Diagnostics, Inc. has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 9, 2026, Co-Diagnostics entered a Loan Agreement with J.J. Astor & Co. for up to $3.1 million, with an initial $2.1 million funded at closing against a note with an original principal of $2.835 million. The notes are secured by substantially all company and subsidiary assets, are payable in 30 weekly installments, and can be converted into common stock at a discount to market, which could dilute existing shareholders; ATM sale proceeds are also routed to the lender.
Initial loan funded: $2.1 million; initial note original principal: $2.835 million; net initial proceeds about $2.016 million after a 4% origination fee
Conversion price is the greater of 90% of the lowest 10-day VWAP and the Nasdaq-based floor, with 600,000 commitment shares issued to the lender
Initial $1.0 million of ATM net proceeds is payable to the lender, with 80% of later net proceeds applied to the notes
Placement agent Maxim Group LLC receives a 5.0% cash fee on gross proceeds; a 19% default interest rate applies after an event of default
Co-Diagnostics, Inc. filed an 8-K stating it will host an investor and analyst presentation on September 16, 2026, covering its collaboration with ReadyGo Diagnostics Ltd., the Co-Dx PCR platform, manufacturing initiatives, and operations in India. The filing contains no financial results, guidance, or new transaction terms; the presentation materials are furnished as Exhibit 99.1.
Investor and analyst presentation scheduled for September 16, 2026
Topics include the ReadyGo Diagnostics Ltd. collaboration and the Co-Dx PCR platform
Presentation materials furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Co-Diagnostics said it is working with UK-based ReadyGo Diagnostics to evaluate whether ReadyGo's blood sample-preparation technology can work with the Co-Dx PCR platform, starting with decentralized Ebola detection. The filing describes early feasibility work only, with no financial terms, and the companies say there is no assurance the evaluation will succeed or lead to a commercially available product.
Collaboration with ReadyGo Diagnostics Ltd. announced September 16, 2026, with an initial focus on decentralized Ebola virus detection
Feasibility work has begun, and Co-Diagnostics has taken delivery of ReadyGo materials and devices for the evaluation
The Co-Dx PCR platform has not been cleared or authorized by the FDA and is not yet available for sale
Live press conference and webcast scheduled for September 16, 2026, at 10:30 a.m. ET
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Co-Diagnostics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →